Olema Oncology
Srini Jayaraman is a seasoned professional in the field of nonclinical operations, currently serving as the Nonclinical Operations Manager at Olema Oncology. With extensive experience as an Independent Nonclinical Operations Consultant, Srini Jayaraman previously held various roles at Denali Therapeutics, advancing from Manager to Associate Director in Nonclinical Externalization Operations. Prior contributions include positions at BASi as Principal Investigator in Preclinical PK/PD Services and as Associate Principal Scientist at Merck, where expertise in In Vivo Pharmacology was developed. Academic credentials consist of a PhD in Neuropharmacology from Eberhard-Karls-Universität and a B.Pharm and M.Pharm in Pharmacology from Tamil Nadu Doctor M.G.R. Medical University.
Olema Oncology
Olema Oncology is a biopharmaceutical company developing innovative targeted therapies for women’s cancers. Their lead program, OP-1250, a potential best-in-class complete estrogen receptor antagonist (CERAN), is in development to treat estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. Olema recently initiated a Phase 1/2 dose-escalation and expansion clinical trial of OP-1250. They are supported in their mission by experienced and accomplished scientists and board members, leading healthcare investors and some of the most innovative pharma companies.